| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015906 |
| Receipt No. | R000018333 |
| Scientific Title | Diagnostic accuracy of diastolic fractional flow reserve (d-FFR) for functional evaluation of coronary stenosis |
| Date of disclosure of the study information | 2014/12/10 |
| Last modified on | 2020/10/08 (Ver. 10) |
| Basic information | ||
| Public title | Diagnostic accuracy of diastolic fractional flow reserve (d-FFR) for functional evaluation of coronary stenosis | |
| Acronym | DIASTOLE Study | |
| Scientific Title | Diagnostic accuracy of diastolic fractional flow reserve (d-FFR) for functional evaluation of coronary stenosis | |
| Scientific Title:Acronym | DIASTOLE Study | |
| Region |
|
|
| Condition | ||
| Condition | Stable coronary disease with a single major coronary artery lesion | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare diagnosis accuracy rate of diastolic FFR (d-FFR) and conventional full cardiac cycle FFR to scintigraphy for a single major coronary vessel lesion |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The difference of the accuracy rate from the d-FFR and full cardiac cycle FFR using myocardial scintigraphy as a golden standard |
| Key secondary outcomes | 1) The cutoff value of d-FFR and FFR using myocardial scintigraphy as a golden standard
2) Assess the sensitivity and the specificity, the positive-predictive value, the negative-predictive value of diastolic Pd/Pa at rest and Pd/Pa at rest using myocardial scintigraphy as a golden standard 3) The cutoff value of diastolic Pd/Pa at rest and Pd/Pa at rest using myocardial scintigraphy as a golden standard 4) Assess the sensitivity and the specificity, the positive-predictive value, the negative-predictive value of myocardial scintigraphy using FFR as a golden standard 5) Assess the sensitivity and the specificity, the positive-predictive value, the negative-predictive value of myocardial scintigraphy using d-FFR as a golden standard |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patient who is adaptable to coronary angiography (CAG) or coronary revascularization (PCI/CABG)
2) Patient who has stable coronary artery disease with more than 50% diameter stenosis in a single major coronary artery on CAG by visual estimation 3) Age>=20 years old at time of getting informed consent 4) Patient who can understand and voluntarily sign the informed consent form |
|||
| Key exclusion criteria | 1) Patient who has left main trunk lesion
2) Chronic total occlusion (CTO) lesion 3) lesion that is in-stent restenosis 4) Patient who has multivessel coronary artery disease 5) Patient who is diagnosed with ST-segment elevation acute myocardial infarction 6) Culprit lesion of non ST-segment elevation acute coronary syndrome 7) Patient who has anamnesis of old myocardial infarction 8) Patient who meets a contraindication of ATP (Adenosine triphosphate disodium hydrate) 9) Patient with frequent ventricular extrasystole, and with atrial/auricular flutter or fibrillation 10) Patient who is diagnosed left heart failure or altitude valvular disease 11) Patient with a history of coronary artery bypass graft (CABG) 12) Patient with severe renal dysfunction (eGFR < 30mL/min/1.73m2) 13) Patient who doesn't agree to provide the informed consent 14) Patient is concluded unsuitable by a docter in charge of the present clinical research |
|||
| Target sample size | 413 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Wakayama Medical University Hospital | ||||||
| Division name | Department of Cardiovascular Medicine | ||||||
| Zip code | 641-8509 | ||||||
| Address | 811-1 Kimiidera, Wakayama-shi, Wakayama 641-8509, Japan | ||||||
| TEL | 073-447-2300 | ||||||
| akasat@wakayama-med.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | The study secretariat of DIASTOLE Study | ||||||
| Division name | Soiken Inc. | ||||||
| Zip code | 101-0052 | ||||||
| Address | NFB Ogawa-cho Bldg 4F, 1-3-1, Kanda Ogawa-cho, Chiyoda-ku, Tokyo | ||||||
| TEL | 03-3295-1350 | ||||||
| Homepage URL | |||||||
| takayama@soiken.com | |||||||
| Sponsor | |
| Institute | NPO Association for Thinking about the Future of the Heart Angioplasty |
| Institute | |
| Department | |
| Funding Source | |
| Organization | NPO Association for Thinking about the Future of the Heart Angioplasty |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Research Ethics Committee of Wakayama Medical University |
| Address | 811-1 Kimiidera, Wakayama, Wakayama |
| Tel | 073-447-2300 |
| wa-rinri@wakayama-med.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | * Prospective, multicenter
* From 2014/9/1 to 2020/8/31 * Enrollment: Until 2020/2/28 |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018333 |